Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOv19-BBz CAR T cells in recurrent ovarian cancer
NCT03585764Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2018
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MOv19-BBz in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (4 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Number of Study Subjects With Treatment-related Adverse Events at 34 months, Manufacturing Feasibility at 8 weeks and 1 more. Started Oct 2018; status: terminated.
02
Drugs
MOv19-BBz
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03585764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585764.